Latest News and Press Releases

Oslo, Norway, 16 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that members of its senior management...

Oslo, Norway, 3 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its first quarter 2018 results. ...

Responses observed in three out of six patients Recruitment into the randomized part of the trial underway Oslo, Norway, 2 May 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused...

Reference is made to the annual general meeting of Targovax ASA (the "Company") on 11 April 2018 (the "AGM") where election of members to the board of directors was according to the nomination...

Oslo, Norway, 25 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumours, have today presented at the ChinaBio...

Oslo, Norway, 24 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, will announce its first quarter 2018 results...

Oslo, Norway, 12 April 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces the appointment of Catherine...

The annual general meeting was held on April 11, 2018 at the Company's offices at Lilleakerveien 2C, 0283 Oslo. Please find minutes of the meeting attached. For further information,...

Reference is made to the notice published on 15 March 2018 regarding the annual general meeting in Targovax ASA (the "Company") to be held on 11 April 2018 at 10:00 am (CEST). The proposal by the...

On 14 March 2018, the board of directors of Targovax ASA approved the company's financial statements for 2017, which will be dealt with by the Company's annual general meeting on 11 April 2018. The...